Summary
The GABA-A receptor agonist THIP, or the mixed GABA-A/GABA-B receptor agonist progabide dose dependency increased the release of norepinephrine (as measured by the production of MHPG) in the cerebral cortex and hippocampus. This effect was partially reversed by treatment with the GABA-A receptor antagonist bicuculline. In contrast, the GABA-B receptor agonist baclofen decreased the release of norepinephrine in the cerebral cortex and hippocampus. Pretreatment with the presynaptic noradrenergic neurotoxin DSP4 increased the Bmax for beta-adrenergic receptor binding in the cerebral cortex and hippocampus. This effect was partially prevented by chronic (14 day) treatment with either the beta-adrenergic agonist clenbuterol or the GABA-B receptor agonist baclofen. In contrast, chronic (14 day) administration with either the GABA-A receptor agonist THIP or the antidepressant imipramine failed to alter the increase in betaadrenergic receptor binding produced by DSP4 pretreatment. These data suggest that the GABA-A receptor may be coupled to the presynaptic noradrenergic neuron and modulate the release of norepinephrine, while the GABA-B receptor is coupled to the postsynaptic noradrenergic neuron and likely functions through the cyclic AMP generating system.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Andrews, P. R., Johnston, G. A. R.: GABA agonists and antagonists. Biochem. Pharmacol.28, 2697–2703 (1979).
Anden, N., Wachtel, H.: Biochemical effects of baclofen (beta-parachloro-phenyl-GABA) on dopamine and noradrenaline in the rat brain. Acta Pharmacol. Toxicol.40, 310–320 (1977).
Bowery, N. G., Hill, D. R., Hudson, A. L.: Evidence that SL75102 is an agonist at GABA-b as well as GABA-a receptors. Neuropharmacology21, 391–397 (1982).
Bowery, N. G., Hill, D. R., Hudson, A. L., Doble, A., Middlemiss, D. N., Shaw, J., Turnbull, M.: Baclofen decreases neurotransmitter release in the mammalian CNS by an action at a novel GABA receptor. Nature283, 92–94 (1980).
Bradford, M. M.: A rapid and sensitive method for the quantification of microgram quantities of protein using the principle of protein dye binding. Anal. Biochem.72, 248–252 (1976).
Bylund, D. B.: Analysis of receptor binding data, in Receptor Binding Techniques. In: Neuroscience Short Course Syllabus, pp. 70–99.1980.
Desarmenien, M., Feltz, P., Loeffler, J. P., Occhipinti, G., Santangelo, F.: Multiple GABA receptors on A8 and C primary afferent neurons in the adult rat. Br. J. Pharmacol.76, 289–293 (1982).
Dolphin, A., Adrien, J., Hamon, M., Bockaert J.: Identity of3H-dihydroaprenolol binding sites and beta-adrenergic receptors coupled with adenylate cyclase in the CNS: Pharmacological properties, distribution and adaptive responsiveness. Mol. Pharmacol.15, 1–10 (1979).
Dooley, D. J., Bittiger, H., Hauser, K. L., Bischoff, S. F., Waldmeier, P. C.: Alteration of central alpha-2 and beta-adrenergic receptors in the rat after DSP4, a selective noradrenergic neurotoxin. Neuroscience9, 889–894 (1983 a).
Dooley, D. J., Hauser, K. L., Bittiger, H.: Differential decrease of the central beta-adrenergic receptor in the rat after subchronic infusion of desipramine and clenbuterol. Neurochem. Int.3, 333–345 (1983 b).
Dunlap, K.: Two types of GABA receptor on embryonic sensory neurons. Br. J. Pharmacol.74, 579–586 (1981).
Ferrari, R. A., Connell, M. J., Ferranio, R. G., Haubrich, D. A.: Measurement of 1-(4-hydroxy-3-methoxy)ethane-1,2-diol (MOPEG) in mouse brain and cat CSF by HPLC with electrochemical detection: Effects of yohimbine and mianserin. Soc. Neurosci. Abst.8, 887 (1982).
Guidotti, A., Corda, M. G., Wise, B. C., Vaccarino, F., Costa, E.: GABA-ergic synapses: supramolecular organization and biochemical regulation. Neuropharmacol.22, 1471–1479 (1983).
Hall, H., Ross, S. B., Sallemark, M.: Effect of destruction of central noradrenergic and serotonergic nerve terminals by systemic neurotoxins on the long-term effects of antidepressants on beta-adrenoceptors and 5-HTB binding sites in the rat cerebral cortex. J. Neural Transm.59, 9–23 (1984).
Hill, D. R., Bowery, N. G.:3H-baclofen and3H-GABA bind to bicucullineinsensitive GABA-B sites in rat brain. Nature290, 149–151 (1981).
Hill, D. R., Bowery, N. G., Hudson, A. L.: Inhibition of GABA-B receptor binding by guanyl nucleotides. J. Neurochemistry42, 652–657 (1981).
Jonsson, G., Hallman, H., Ponzio, F., Ross, S.: DSP4 (N-[2-chloroethyl]-N-ethyl-2-bromobenzylamine)-A useful denervation tool for central and peripheral noradrenergic neurons. Eur. J. Pharmacol.72, 173–179 (1981).
Karbon, E. W., Duman, R., Enna, S. J.: Biochemical identification of multiple GABA-B binding sites: association with noradrenergic terminals in rat forebrain. Brain Res.274, 393–396 (1982).
Karbon, E. W., Enna, S. J.: GABA agonists potentiate norepinephrine-stimulated adenylate cyclase in rat brain frontal cortex slices. Soc. Neurosci. Abst.13, 55 (1983).
Kinnier, W. J., Chuang, D. M., Costa, E.: Down-regulation of3H-dihydroaprenolol and imipramine binding sites in brain of rats repeatedly treated with imipramine. Eur. J. Pharmacol.67, 289–295 (1980).
Korf, J., Venema, K.: DMI enhances the release on endogenous GABA and other neurotransmitter amino acids from rat thalamus. J. Neurochem.40, 946–955 (1983).
Krogsgaard-Larsen, P., Hjeds, H., Curtis, D. R., Lodge, D., Johnston, G. A. R.: Dihydromuscimol, thiomuscimol, and related heterocyclic compounds as GABA agonists. J. Neurochem.32, 1717–1726 (1979).
Lloyd, K. G., Morselli, P. L., Depoortere, H., Fournier, V., Scatton, B., Broekkamp, C., Worms, P., Bartholini, G.: The potential use of GABA agonists in psychiatric disorders: Evidence from studies with Progabide in animal models and clinical trials. Pharmacol. Biochem. Behav.18, 959–963 (1983).
Magnusson, O., Nilsson, L. B., Westerlund, D.: Simultaneous determination of dopamine, DOPAC and homovanillic acid. Direct injection of supernatents from brain tissue homogenates in a liquid chromatographyelectrochemical detection system. J. Chromatography221, 237–247 (1980).
Muhyaddin, M. S., Roberts, P. J., Woodruff, G. N.: Presynaptic GABA-B receptors and the regulation of3H-noradrenaline release from rat anococcygus muscle. Eur. J. Pharmacol.92, 9–14 (1983).
Scatton, B., Zivkovic, B., Dedek, J., Lloyd, K. G., Constantinidis, J., Tissot, R., Bartholini, G.: GABA receptor stimulation. 3. Effect of progabide (SL 76002) on norepinephrine, dopamine and 5-hydroxytryptamine turnover in rat brain areas. J. Pharmacol. Exp. Ther.220, 678–688 (1982).
Schweitzer, J. W., Schwartz, R., Friedhoff, A. J.: Intact presynaptic terminals required for beta-adrenergic receptor regulation by desipramine. J. Neurochemistry33, 377–379 (1979).
Sulser, F., Mobley, P. L.: Regulation of central noradrenergic receptor function: New vistas on the mode of action of antidepressant treatment. In: Neuroreceptors: Basic and Clinical Aspects, pp. 321–335. 1981.
Suzdak, P. D., Gianutsos, G.: Parallel changes in GABA-ergic and noradrenergic receptor sensitivity following chronic administration of antidepressant and GABA-ergic drugs: A possible role of GABA in affective disorders. Neuropharmacol. (submitted, 1984).
Zivkovic, B., Scatton, B., Dedek, J., Bartholini, G.: GABA influence on noradrenergic transmissions: implications in mood regulation. Adv. Biosci.40, 195–201 (1982).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Suzdak, P.D., Gianutsos, G. Differential coupling of GABA-A and GABA-B receptors to the noradrenergic system. J. Neural Transmission 62, 77–89 (1985). https://doi.org/10.1007/BF01260417
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF01260417